StemEdit hiPSC B2M/CIITA DKO RPC-LLF-34-F3
| Cat # | Size |
|---|---|
| RCRP052 | 1 vial (1 million cells) |
Overview
Ready-to-use Research-Grade HLA Class I and II double knockout iPSCs made using REPROCELL’s RNA Reprogramming Technology.
These cells feature all the advantages of our RNA reprogramming technology, including no retention of reprogramming factors and easy culture in NutriStem hPSC XF Medium (Cat. No. 01-0005) on iMatrix-511 (Cat. No. NP892-011). They have been engineered using OpenCRISPR-1 to contain B2M (HLA Class I) and CIITA (HLA Class II) double knockout mutations, which are carefully characterized and offer significant time savings compared to creating your own reprogrammed and edited cell lines.
NOTE:
These iPSC cell lines are developed and supplied for Research Use Only (RUO). They are not intended for clinical or therapeutic applications. However, this clone has a clinical-grade counterpart available that is suitable for clinical gene editing and downstream clinical development. If you require material for translational or clinical programs, please see Clinical Stem Cell Services or Contact Us for more information.
See also our complete collections of Research Use Only StemRNA™ Induced Pluripotent Stem Cells (iPSCs) and StemEdit Gene-Edited iPSC Lines.
Table: Characteristics of StemEdit hiPSC B2M/CIITA DKO RPC-LLF-34-F3 Cells
| Cat. No.: | RCRP052 |
| Mutation: | B2M/CIITA double knockout |
| Mutation validation: |
DNA Sequencing, B2M expression (flow) |
| Parent Clone ID: |
StemRNA Clinical iPSC Clone LLF-34-F3 |
| Donor Blood Type: |
O positive |
| Donor Race: | Caucasian |
| Donor Sex: | Female |
| Donor Age: | 22 |
| Reprogramming Technology: | StemRNA Clinical Reprogramming Technology |
| Tissue Source: | Skin (Fibroblasts) |
| Karyotype: | Normal (46 XX) |
| Microbiology: | Negative for bacteria, viruses, and mycoplasma |